272778-13-9

Basic information

• Product Name: (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one
• Synonyms: (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one;(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-((trimethylsilyl)-oxy)propyl)-4-(4-((trime;2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-[(triMethylsilyl)oxy]propyl]-4-[4-[(triMethylsilyl)oxy]phenyl]-, (3R,4S)-;(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-((trimethylsilyl)-oxy)propyl)-4-(4-((tr
• CAS NO: 272778-13-9
• Molecular Formula: C30H37F2NO3Si2
• Molecular Weight: 553.794
• Product Categories: Ezetimibe intermediates
• Mol File: 272778-13-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.118
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one(272778-13-9)
• EPA Substance Registry System: (3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one(272778-13-9)

Safety Data

• Hazardous Substances Data: 272778-13-9(Hazardous Substances Data)

Usage

General Description

The chemical "(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl-3-(trimethylsilyloxy)propyl)-4-(4-(trimethylsilyloxy)phenyl)azetidin-2-one" is a complex compound that contains a fluorophenyl group and an azetidin-2-one ring structure. It also features trimethylsilyloxy groups attached to the phenyl and propyl moieties. The compound has a chiral nature, with the (3R,4S) and (S) configurations denoting the stereochemistry of the molecule. This chemical may have potential applications in pharmaceuticals or organic synthesis due to its unique structure and functional groups. However, further research would be needed to fully understand and utilize the properties and potential uses of this compound.

Upstream product

• 272778-12-8 (4S)-3-[(2R,5S)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenyl)amino]({4-[(trimethylsilyl)oxy]phenyl})methyl]-5-[(trimethylsilyl)oxy]pentanoyl]-4-phenyl-1,3-oxazolidin-2-one 
• 1296129-16-2 3-[(2R,5R)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenylamino)(4-hydroxyphenyl)methyl]-5-hydroxy-1-oxo-pentyl]]-4(S)-phenyl-2-oxazolidinone 
• 75-77-4 chloro-trimethyl-silane 
• 870634-36-9 methyl 5S-5-(4-fluorophenyl)-5-hydroxyvalerate 
• 3382-63-6 N-(4-hydroxybenzylidene)-4-fluorobenzenamine 
• 1185883-40-2 C₃₃H₃₀F₂N₂O₅ 
• 189028-95-3 (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidine-2-one 

Relevant articles and documents

Preparation method of ezetimibe and intermediate thereof

The invention discloses a preparation method of ezetimibe and an intermediate thereof. The invention provides a preparation method of an ezetimibe intermediate IV. The preparation method comprises thefollowing steps: an ezetimibe intermediate II and an ezetimibe intermediate III are subjected to a cyclization reaction to obtain the ezetimibe intermediate IV in the presence of a trialkylchlorosilane, an organic base, a chiral catalyst and lithium diisopropylamide in an organic solvent, wherein R is methyl, ethyl or propyl. The preparation method is short in route steps, mild in reaction conditions and simple in post-treatment steps, and avoids the connection of a substrate with a chiral group, and the obtained product is high in purity, achieves the standard of bulk drugs, is high in yield, low in production cost, high in atomic utilization rate, and suitable for industrial production.

According to booklet according to booklet mai bu and mai bu intermediates of the synthesis method

The invention relates to an ezetimibe intermediate and a synthesis method of ezetimibe, and mainly solves the technical problems of low yield, low purity, severe conditions and the like in existing methods. According to a technical scheme of the invention, the preparation method includes: subjecting a compound 1 to Aldol condensation reaction under the condition of a self-made isopropoxy titanium trichloride catalyst to generate a compound 2, controlling the Aldol condensation temperature below -5DEG C, in terms of dropwise adding of the catalyst, adding a system A into a catalyst system, conducting ring closing on a compound 2 under the catalysis of TBAF, and removing silicon protecting group under the fluoride salt condition to generate ezetimibe. The synthesis route has mild conditions, the obtained intermediate and end product have high yield, and the purity is high.

Slurry bed continuous production method of ezetimibe intermediate

The invention discloses a continuous production method of an ezetimibe intermediate 3-[(2R,5S)-5-(4-fluorophenyl)-2-[(S)-[(4-fluorophenyl(amino))][4-R1oxo]phenyl]methyl]-1-oxo-5-[(trimethylsilicon)oxo]phenyl]-4-phenyl-(4S)-2-oxazolidinone. The ezetimibe intermediate is prepared through a contact reaction of raw materials containing a compound A and a compound B with a solid acid catalyst in a slurry bed reactor. The solid acid catalyst is adopted to substitute original titanium tetrachloride and isopropyl titanate catalysts, and a continuous reaction is carried out in the slurry bed reactor, so the method reduces environment pollution and production device requirements, solves the separation and recovery problems of the catalysts, and makes large-scale continuous production of ezetimibe become possible.